Sun Pharma resolves FDA warning letter

MUMBAI, India — Sun Pharmaceutical Industries last month said that it has resolved issues cited in a warning letter sent to the company by the Food and Drug Administration pertaining to one of Sun Pharma's U.S.-based manufacturing facilities.

The generic drug maker said its wholly owned subsidiary received the go-ahead from the FDA following a reinspection of the plant, located in Cranbury, N.J., which was conducted this past June. The warning letter, which was issued Aug. 25, 2010, was considered resolved after the plant was declared as having acceptable regulatory status.

Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.